Non-opioid Pain Treatment Market Size & Share, by Drug Class (NSAIDs, Acetaminophen, Local Anesthetics); Pain Type; Route of Administration; Distribution Channel - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

North America Market Analysis

The non-opioid pain treatment market in North America is expecting its dominance during the forecast timeline with a notable share of 54.2%. Prescription opioids are evidently utilized in the region to treat darting and discomfort pain owing to chronic difficulties. However, these are not advocated as first-line treatments for a variety of pains since there is a risk of overdose and opioid use disorder (OUD). Opioid overdose and OUD deaths are crucial public health concerns in the region, and the trends and pattern evaluation of these opioids contribute towards the promotion of effective and safe treatments for the management of pain.

Percentage of America population using opioids

Source: Medical Expenditure Panel Survey, September 2023

The U.S. non-opioid pain treatment market is gaining traction due to the rise in the opioid crisis, wherein the misuse and overuse have resulted in more than 80,000 opioid-related deaths, as published by IQVIA report in May 2024. In addition, the report also stated that the prevalence of rare disease pain of lower back, neck, and migraine pain has affected 619 million people in the country which is projected to increase to 843 million by 2050. The American Society of Anesthesiologists ensured medications including physical therapy, and surgery along with technologies such as nerve blocks, radio waves, electrical signals, spinal cord stimulation, and pain pumps as solutions to overcome the issue and boost the market growth.

The non-opioid pain treatment market in Canada is witnessing significant growth due to the presence of both opioid and non-opioid medicines for the diagnosis and treatment of pain. According to the Canadian Cancer Society, opioid-based drugs are undertaken regularly, but for a short period of 2 to 4 hours, while other opioid drugs are time taking for over 12 hours. Buprenorphine (Subutex), codeine, fentanyl (Duragesic), hydrocodone, hydromorphone (Dilaudid), and others are a few opioid drugs. Whereas, non-opioid drug such as acetaminophen is frequently used to ease mild pain and reduce fever, comprising no side effects, thereby uplifting the market evolution.

APAC Market Statistics

The non-opioid pain treatment market in APAC is the fastest-growing region and is poised to gain traction by the end of 2037. As per the Mayo Clinic Organization 2025 report, acupuncture is the utmost pain treatment common in Asian countries which includes the insertion of thin needles on strategic body points through skin. This is a traditional medical treatment, increasingly implemented to maintain overall wellness and manage stress. Discomforts caused by certain conditions including chemotherapy, fibromyalgia, menstrual cramps, respiratory disorders, labor pain, and tennis elbow, all can easily be overcome by the adoption of acupuncture which is positively impacting the market development.

The non-opioid pain treatment market in India is anticipated to experience substantial growth since pain occurrence is a common factor in the country, especially among the elderly population. As per a population-based study conducted on 63,931 people by the International Association for the Study of Pain in February 2023, 36.6% of old patients in the country are often troubled by aching issues and 25.2% experience aches due to regular activities. To combat this, the Ashirvad Institute for Pain Management and Research 2025 provides several treatments including ultrasound-guided dry needling, transforaminal epidural steroid, intraarticular steroid, radio frequency procedures, and regenerative and ozone therapies, all boosting market growth.

The non-opioid pain treatment market in China is gaining traction owing to partnerships and licensing agreements of organizations in the country. For instance, in July 2022, Novaremed AG and NeuroFront Therapeutics Limited jointly declared a collaboration for the development of NRD.E1, an innovative non-opioid investigational drug, for aiding diabetes-related neuropathic pain in China as well as in Singapore. As per the agreement, Novaremed received USD 130 million as an exercise fee for the expansion, regulation, and sales milestone payment pertaining to the drug. Moreover, this deal allowed NeuroFrontto commercialize the drug as a therapy for painful diabetic peripheral neuropathy (PDPN), thus amplifying the market growth.